Detalles de la búsqueda
1.
THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial.
Mov Disord
; 37(2): 410-415, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34709684
2.
A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.
Palliat Med
; 26(1): 50-60, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21937568
3.
Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.
BMC Clin Pharmacol
; 10: 12, 2010 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-20920236
4.
Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.
Addiction
; 113(3): 484-493, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29143400
5.
Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension.
CNS Drugs
; 30(8): 749-60, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27401882
6.
Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.
Lancet Neurol
; 12(12): 1141-50, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24140442
7.
Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management.
J Opioid Manag
; 5(3): 145-51, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19662924
Resultados
1 -
7
de 7
1
Próxima >
>>